Kruppel like factor 10 up-regulates PDZ and LIM domain containing protein 2 via nuclear factor kappa-B pathway to inhibit proliferation and inflammatory of fibroblastoid synovial cell in rheumatoid arthritis

Shan Wang*, Xuwen Zha, Shengting Ruan, Shoulin Yao, and Xiaoyu Zhang

Rheumatology and Immunology Department, the First People's Hospital of Hefei, The Third Affiliated Hospital of Anhui Medical University, Anhui, China

**ABSTRACT**

Rheumatoid arthritis (RA) is an autoimmune disease caused by synovitis. Two genes, KLF10 (Kruppel like factor 10) and PDZ and LIM domain containing protein 2 (PDLIM2), play key roles in cell inflammation and proliferation. However, the specific roles of the two on inflammation and proliferation of RA-fibroblastoid synovial cell (RA-FLS) have not been reported so far. RT-qPCR and Western blot detected the expressions of PDLIM2 and KLF10 in Human Rheumatoid arthritis FLSs (HFLS-RA). Cell transfection techniques overexpressed PDLIM2 and KLF10 or inhibited the expression of KLF10. JAPAR database predicted the binding sites of PDLIM2 and KLF10, and the binding between the two was detected and verified using luciferase reporter genes and ChIP. Subsequently, CCK-8 technology, TUNEL staining, Western blot, wound healing and ELISA detected proliferation-related indicators, migration-related indications and inflammation-related indicators. Finally, western blot was used to detect the expression of NF-κB pathway-related proteins to further explore the mechanism. The expression of PDLIM2 was decreased in HFLS-RA. Overexpression of PDLIM2 inhibited proliferation, migration and inflammation in HFLS-RA. KLF10 can transcriptionally activate PDLIM2. Interfering with KLF10 reversed the inhibition effects of PDLIM2 overexpression on the proliferation, migration and inflammation, which was possibly through the NF-κB pathway. Overall, KLF10 can up-regulate PDLIM2 by regulating the NF-κB pathway to inhibit inflammation and proliferation of HFLSs-RA.

**Introduction**

Rheumatoid arthritis (RA) is characterized by severe bone destruction, which can lead to joint stiffness, deformity, and dysfunction (1). RA patients are at higher risk of disability and other complications than the general population. Moreover, RA is one of the most refractory diseases in the world (2, 3). Thus, it is of great urgency for us to identify novel targets for the complete treatment of RA.

Inflammatory infiltration of synovium and massive neovascularization of synovium and cartilage are the main pathological changes of RA that can lead to joint structural destruction and dysfunction (4). Fibroblastoid synovial cell (FLS) is an important component of synovial tissue, the normal function of which is the premise of maintaining the homeostasis in the joint environment (5). During the progression of RA, FLS is abnormally activated in vitro, showing the characteristics of tumor-like abnormal proliferation and secretion of much inflammatory cytokines (6).

PDZ and LIM domain containing protein 2 (PDLIM2) is a member of the actin-associated Lim protein (ALP) superfamily and is present in the nucleus of many cells. It contains a PDZ domain at the N-terminal and a LIM domain at the C-terminal (7). The LIM domain plays an important role in the regulation of actin cytoskeleton formation, cell differentiation and signal transduction as the domain of protein–egg interaction (8). Studies have shown that PDLIM2 has anti-inflammatory and anti-proliferative effects. PDLIM2 expression was significantly down-regulated in LPS-induced chondrocytes, and overexpression of PDLIM2 alleviated LPS-induced apoptosis, degeneration, and inflammatory injury by inactivation of NF-κB signal (9). PDLIM2...
inhibited NF-κB activation and suppressed lipogenesis and inflammation induced by high-fat diet in mice (10). In addition, PDLIM2 suppression efficiently reduces tumor growth of prostate cancer-like cells (11). However, the effect of PDLIM2 on overproliferation and inflammatory response of FLS in RA has not been reported.

JASPAR database predicted binding of the transcription factor KLF10 to the promoter of PDLIM2 (12). KLF10 (Kruppel like factor 10) plays a crucial role in proliferation and inflammatory response. Study has shown that KLF10 deficiency led to stress-induced liver fibrosis upon high sucrose feeding (13). KLF10 prevented acute viral myocarditis by negatively regulating the expression of myocardial MCP-1 (14). The deficiency of KLF10 in mice increased inflammation in pulmonary disease via increasing the expression of NPRA (15). KLF10 inhibited the proliferation and migration of chondrocytes in osteoarthritis by up-regulating ACVR1 and inhibiting the expression of INHBB (16). KLF10 protein inhibited the proliferation of myoblasts and the activity of fibroblast growth factor receptor 1 promoter (17). However, the interaction between KLF10 and PDLIM2 and their effect on over proliferation and inflammatory response of FLS in RA have not been reported.

In this study, we detected the relationship between KLF10 and PDLIM2 and their effect on overproliferation and inflammatory response of FLS in RA. Our paper provides a theoretical basis for the mechanistic treatment of RA.

Materials and methods

Cell culture

Human Rheumatoid arthritis FLSs (HFLSs-RA) and Normal FLSs from BeiNa Biological Technology Co., Ltd were cultured in DMEM containing 10% FBS and 1% antibiotics/antimycotic solution (all from Thermo Fisher Scientific) at 37°C, and 5% CO₂ in a humidified atmosphere incubator.

RT-qPCR

Based on the manufacturer’s instructions, we isolated the total RNA from cells using QIAzol reagent (Qiagen Inc., Valencia, CA) and the single-stranded cDNAs were synthesized from 1 μg of RNA using ReverAid™ M-MuLV reverse transcriptase (Fermentas). The expression of mRNAs was quantified by RT-PCR with SYBR Green I (Thermo Fisher Scientific, Inc). The following PCR thermocycling conditions were used: 10 min at 95°C; followed by 47 cycles at 95°C for 30 sec, 60°C for 30 sec and 72°C for 60 sec. PCR sequences were as follows: PDLIM2 (Refseq ID: NM_176871) forward, 5'- CTCAGGTAT GGCCTTGACGTTGATG −3', reverse, 5'- GTCTCCTGTTCTCTCCT −3'; KLF10 (Refseq ID: NM_005655) forward, 5'- CCAACCATGCTCAA CTTGGTGCCTCT-3', reverse, 5'- TTCTGACTC TTCACCTTCCGGTCTGC -3'; GAPDH forward, 5'-AGGTCCGCTGAACCAGATTTG-3', reverse, 5' TGTAGACCATTGATTTAGGTCA-3'. Expression was determined by the 2-ΔΔCq method (18). The experiment was repeated three times.

Cell transfection

PDLIM2 overexpression vectors (Ov- PDLIM2) and corresponding negative controls (Ov-NC) were transfected to cells. The coding sequences of KLF10 were subcloned into the pcDNA3.1 plasmids to construct pcDNA3.1-KLF10 expression plasmids. For short hairpin RNA, KLF10 shRNA was inserted into the pLKO.1 plasmids. All transfections were transferred using Lipofectamine 3000 Reagent (Thermo Fisher Scientific). The transfection efficiency of the cells was detected by RT-qPCR 48 h after transfection. All transfection sequences were synthesized by Shanghai Riobo Co., Ltd. Following incubation for 48 h, cells were used for subsequent experiments.

Cell Viability assay

Cell viability was detected by CCK-8 kit (Nanjing Jiancheng Biotechnology Co. LTD) according to the manufacturer’s instructions. Cells (5 × 10³) were plated in 96-well plates and cell growth was determined by using CCK8 assay. Then, cells were given 10 μL CCK-8 solution and cultured for 3 h. Optical density (OD) values were measured at 450 nm with a microplate reader (Bio-Tek Instruments, Winooski, VT, USA).
**TUNEL**

Cell apoptosis was assessed using TUNEL Apoptosis Detection Kit (Beyotime Biotechnology, Shanghai, China) (19). Cells were seeded into 6-well plate (1 × 10^6 cells /well) and then fixed with 4% paraformaldehyde for 30 min at room temperature. Afterward, the cells were incubated with permeabilization solution for 5 min at room temperature followed by TUNEL solution for 1 h at 37°C. Finally, apoptotic cells were observed under a fluorescence microscope (Olympus Corporation, Tokyo, Japan).

**Western blot**

Cells were lysed on ice with RIPA reagent (Beijing Solarbio Science & Technology Co., Ltd.) for 30 min, followed by centrifugation at 250 g for 10 min at 4°C. Protein concentration was determined by BCA kit (Beyotime). 10% SDS-PAGE gels were prepared to separate proteins (30 μg each lane), and then the latter were transferred onto polyvinylidene difluoride (PVDF) membranes (EMD Millipore) and the membrane was blocked with 5% skim milk for 2 h at room temperature followed by primary antibody including anti- PDLIM2 (1:1,000; cat. no. PA5-52,009; Thermo Fisher Scientific), anti- Bcl-2 (1:1,000; cat. no. 33–6100; Thermo Fisher Scientific), anti-Bax (1:1,000; cat. no. ab32503; Abcam), anti- Cyto-C (1:1,000; cat. no. ab133504; Abcam), anti-Cleaved caspase 3 (1:1,000; cat. no. PA5-114,687; Thermo Fisher Scientific), anti- caspase 3 (1:1,000; cat. no. PA5-77,887; Thermo Fisher Scientific), anti- MMP2 (1:1,000; cat. no. ab92536; Abcam), anti- MMP9 (1:1,000; cat. no. ab76003; Abcam), anti- Cox2 (1:1,000; cat. no. ab179880; Abcam), anti- iNOS (1:1,000; cat. no. ab178945; Abcam), anti- KLF10 (1:1,000; cat. no. ab73537; Abcam) and anti-GAPDH (1:1,000; cat. no. ab8245; Abcam). The membranes were then incubated with the respective horseradish peroxidase (HRP)-labeled secondary antibody. Protein blots were visualized with the method of chemiluminescence and quantified using Image J (Version146; National Institutes of Health) (20).

**Wound healing**

Cells were seeded into a six-well plate (1 × 10^6 cells /well) containing the culture medium (DMEM with 10% FBS). The cells were wounded with a pipette tip after cell transfection and the cells grew to 95% confluence. After 24 h of growth in serum-free medium, images of the cells were pictured by microscope (21).

**ELISA**

The concentrations of cytokines in the cell culture medium were determined by ELISA for human IL-1β (H002), IL-6 (H007-1-1) and TNF-α(H052-1) from Jiangcheng Biotechnology Co. Ltd (Nanjing, China) with the manufacturer’s instructions.

**Luciferase reporter assay**

Wild-type (WT) or mutant (MUT) promoters of PDLIM2 were inserted into pGL3 vectors and cotransfected with plasmids containing KLF10 or NC into HFLSs-RA using Lipofectamine 2000 Reagent (Thermo Fisher Scientific). After the transfection for 48 h and the cells were measured by Dual Luciferase Reporter Assay System (Promega Corporation, Fitchburg, WI, USA). Luciferase activities were expressed as the luminescence of Firefly relative to Renilla (22).

**ChIP assay**

The relationship between KLF10 and PDLIM2 was detected by SimpleChIP Kit (Cell Signaling Technology). 1% formaldehyde was used to cross-link with cells, and then the cells were lysed to prepare nuclei. Upon incubating the digested chromatin with anti-KLF10 antibody (ab73537), anti-PDLIM2 antibody (ab246868) or normal rabbit IgG (negative control; all from Abcam) at 4°C overnight, ChIP-grade protein G magnetic beads were used to pull down the immune complexes. After eluting chromatin from the antibody/protein G magnetic beads, DNA was purified using the spin column provided with the kit (23).
Statistical analysis

SPSS20.0 was used to analyze the data, which were expressed as means ± standard of mean (SD). One-way ANOVA was employed to assess differences among different groups, followed by Tukey’s post-hoc test. GraphPad Prism 8.0 software was adopted to dispose all the photographs. \( P < 0.05 \) was considered as statistically significant.

Results

The expression of PDLIM2 was decreased in HFLSs-RA, and overexpression of PDLIM2 inhibited excessive proliferation and induced apoptosis in HFLSs-RA

RT-qPCR was used to detect the expression of PDLIM2 in normal-FLSs and RA-FLSs, and the results showed that the expression of PDLIM2 in RA-FLSs was significantly decreased compared with that in normal-FLSs (\( P < 0.001, \text{Figure 1(a-b)} \)). Subsequently, the transfection efficiency was detected by western blot and RT-qPCR. As shown in Figure 1(c-d), after the overexpression of PDLIM2 by cell transfection technique, we found that the expression of PDLIM2 was obviously increased in Ov-PDLIM2 compared with Ov-NC group (\( P < 0.001 \), meaning successful cell transfection. The results of CCK8 assay showed that the cell viability of Ov-PDLIM2 group was significantly decreased compared with Ov-NC group (\( P < 0.001, \text{Figure 1(e)} \)). TUNEL and Western blot assay showed that apoptosis was significantly increased in the Ov-PDLIM2 group compared with Ov-NC group (\( P < 0.001, \text{Figure 1(f)} \), accompanied by decreased expression of Bcl-2 and increased expression of Cyto-C, Bax, and cleaved caspase3 (\( P < 0.001, \text{Figure 1(g)} \)). These results indicated that overexpression of PDLIM2 inhibited excessive proliferation and induced apoptosis in RA-FLSs.

Overexpression of PDLIM2 inhibited the migration of RA-FLSs

Wound healing assay was used to detect cell migration. We found that cell migration was significantly reduced in the Ov-PDLIM2 group compared to the Ov-NC group (\( P < 0.001, \text{Figure 2(a)} \)). Subsequently, the expression of MMP2 and MMP9 was detected by Western blot. The expression of MMP2 and MMP9 was significantly decreased after overexpression of PDLIM2 (\( P < 0.001, \text{Figure 2(b)} \)). The results showed that overexpression of PDLIM2 inhibited the migration of RA-FLSs.

Overexpression of PDLIM2 attenuated the inflammatory response in RA-FLSs

The levels of inflammatory cytokines TNF-\( \alpha \), IL-1\( \beta \) and IL-6 in cells were detected by ELISA. The results showed that the expression of inflammatory cytokines was significantly decreased in the Ov-PDLIM2 group compared with Ov-NC group (\( P < 0.001, \text{Figure 3(a)} \)). Western blot was used to detect the expression of COX2 and iNOS, and we found that compared with Ov-NC, the expression of COX2 and iNOS in Ov-PDLIM2 group was significantly decreased (\( P < 0.001, \text{Figure 3(b)} \)). The results showed that overexpression of PDLIM2 alleviated the inflammatory response in RA-FLSs.

KLF10 transcriptionally activated PDLIM2

We used the JAPSAR database to predict the binding site of the transcription factor KLF10 and PDLIM2 promoter (Figure 4(a)). Then, the expression of KLF10 in Normal-FLSs and RA-FLSs was detected by RT-qPCR and Western blot. The results showed that KLF10 expression was significantly decreased in RA-FLSs (Figure 4(b)). KLF10 interference or overexpression plasmids were then constructed. Transfection efficiency was determined by RT-qPCR and Western blot. Compared with shRNA-NC, the expression of KLF10 in shRNA-KLF10#2 decreased more significantly in Figure 4(c). We selected shRNA-KLF10#2 for follow-up experiments. Compared with pcDNA3.1, the expression of KLF10 in pcDNA3.1-KLF10 group was significantly increased (Figure 4(c)). Subsequently, luciferase assessed promoter activity and verified the binding between KLF10 and PDLIM2. In the absence of PDLIM2 mutation, overexpression of KLF10 significantly increased luciferin activity in cells (Figure 4(d)). ChIP also confirmed that KLF10 bound to the PDLIM2
promoter S1 element (Figure 4(e)). It was subsequently found that PDLIM2 expression was significantly down-regulated in the Ov-PDLIM2 + shRNA-NC group compared with that in the Ov-PDLIM2 + shRNA-KLF10 group (Figure 4(f)). These results indicated that the expression of PDLIM10 was significantly inhibited after KLF10 expression was inhibited. The above results suggest that KLF10 can transcriptionally activate PDLIM2.
Figure 2. Overexpression of PDLIM2 inhibited the migration of HFLSs-RA. A. Wound healing was used to detect the migration of HFLSs-RA. B. The expression of MMP-2 and MMP-9 in HFLSs-RA after transfection were detected by western blot. ***p < 0.001 vs Ov-NC.

Figure 3. Overexpression of PDLIM2 attenuated the inflammatory response in HFLSs-RA. A. ELISA assay was used to detect the expression of TNF-α, IL-1β and IL-6. B. The expression of Cox2 and iNOS were detected with Western blot. ***p < 0.001 vs Ov-NC.
Interfering KLF10 reversed the inhibitory effects of PDLIM2 overexpression on the proliferation, migration and inflammation of RA-FLSs

We divided the cells into Ov-NC, Ov-PDLIM2, Ov-PDLIM2 + shRNA-NC, and Ov-PDLIM2 + shRNA-KLF10. Results showed that cell viability was significantly increased in the Ov-PDLIM2 + shRNA-KLF10 group compared with that in the Ov-PDLIM2 + shRNA-NC group (Figure 5(a)). Western blot assay detected increased expression of Bax, Cyto-C and Cleaved caspase 3 and decreased Bcl-2 in Ov-PDLIM2+ shRNA-NC group compared with Ov-PDLIM2 + shRNA-NC group (Figure 5(b)). TUNEL assay showed that apoptosis was significantly increased in Ov-PDLIM2+ shRNA-NC group compared with Ov-PDLIM2 + shRNA-NC group (Figure 5(c)). Wound healing and Western Blot techniques were used to detect the migration ability of cells, and the results showed that compared with the
Ov-PDLIM2 + shRNA-NC group, cell migration ability was significantly increased in the Ov-PDLIM2+ shRNA-KLF10 group (Figure 5(d)), accompanied by increased expression of MMP2 and MMP9 (Figure 5(e)). In addition, we also detected the levels of inflammatory cytokines, ELISA and Western blot results showed that compared with the OV-PDLIM2+ shRNA-NC group, the expressions of TNF-α, IL-1β, IL-6, COX2 and iNOS in OV-PDLIM2+ shRNA-KLF10 group were significantly increased (Figure 6(a-b)). These results suggested that interfering with KLF10
reversed the inhibitory effects of PDLIM2 overexpression on the proliferation, migration and inflammation of RA-FLSS cells.

**KLF10/ PDLIM2 modulated the NF-κB pathway**

In the experimental process, we found that the expression of NF-κB pathway related protein p-IκBα and p-NF-κB decreased significantly after overexpression of PDLIM2 compared with Ov-NC group. Further inhibition of KLF10 expression reversed the expression of p-IκBα and p-NF-κB (Figure 6(c)). These results suggest that KLF10/ PDLIM2 may play a role in the proliferation, migration and inflammation of RA-FLSSs by regulating the NF-κB pathway.

**Discussion**

RA is a chronic autoimmune disease characterized by synovitis of the joints and the secretion of autoantibodies (24). As inflammation and synovial hyperplasia are the main pathological features of RA, inhibiting inflammatory response and

![Figure 6. Interfering KLF10 reversed the inhibitory effects of PDLIM2 overexpression on the inflammation of HFLSs-RA through NF-κB pathway. A. ELISA assay was used to detect the expression of TNF-α, IL-1β and IL-6 in HFLSs-RA after transfection. B. The expression of Cox2 and iNOS in HFLSs-RA after transfection were detected with Western blot. C. The expression of NF-κB pathway-related proteins in HFLSs-RA after transfection were detected with Western blot. ***p < 0.001 vs Ov-NC.#p < 0.05, ##p < 0.01, ###p < 0.001 vs Ov-PDLIM2 + shRNA-NC.](image-url)
synovial cell proliferation can be considered as an effective therapeutic therapy against RA (25). FLSs are crucial cells that play a key role in the pathogenesis of RA (26). Under pathological conditions, FLSs will abnormally proliferate with insufficient apoptosis, and secrete high levels of pro-inflammatory cytokines, such as TNF-α, IL-1, IL-6, and IL-17, as well as chemical chemokines and matrix protein-degrading enzymes (5). Therefore, anti-proliferation of FLSs and inhibition of inflammatory response are an effective means for RA treatment. In this study, we examined the proliferation of FLSs and inflammation-related markers in RA to measure the extent of improvement in RA disease. We found that overexpression of PDLIM2 inhibited excessive proliferation, migration, and inflammatory response of HFLSs-RA. To further explore the mechanism, we found that KLF10 transcriptionally activates PDLIM2 through JASPAR database. The transcriptional relationship between PDLIM2 and KLF10 was also verified by experiments. Finally, we found that interfering with KLF10 reversed the inhibitory effect of PDLIM2 overexpression on proliferation, migration and inflammation of HFLSs-RA.

Synovial hyperplasia is an important feature in the pathological process of RA, which directly leads to joint dysfunction after eroding bone and cartilage, and is characterized by tumor-like proliferation (27). Studies have shown that PDLIM2 has a regulatory effect on cell proliferation in tumors. PDLIM2 plays a role as a tumor suppressor gene in non-small cell lung cancer by down-regulating the NF-κB signaling pathway (28). PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells (11). PDLIM2 negatively regulates β-catenin to prevent malignant phenotypes in hepatocellular carcinoma cells (29). In this study, we found that the expression of PDLIM2 was decreased in HFLSs-RA, and overexpression of PDLIM2 inhibited excessive proliferation and induced apoptosis in HFLSs-RA.

PDLIM2 also plays an important role in the regulation of inflammatory response. Its expression is significantly down-regulated in LPS-induced chondrocytes, and PDLIM2 protects articular chondrocytes from LPS-induced apoptosis, degeneration, and inflammation by down-regulating the NF-κB signaling pathway (9). PDLIM7 works synergically with PDLIM2 and P62/SQSTM1 to inhibit inflammatory by promoting the degradation of the p65 subunit of NF-κB (30). PDLIM2 inhibits NF-κB activation and suppresses lipogenesis and inflammation induced by high-fat diet in mice (10). Our results suggest that overexpression of PDLIM2 can reduce the expression of inflammatory factors TNF-α, IL-1β, IL-6, COX2 and iNOS in HFLSs-RA.

JASPAR database predicts that transcription factors KLF10 and PDLIM2 promoters have binding sites. The combination between the two was verified by the luciferase reporter gene, ChIP technology. In addition, inhibition of KLF10 expression could inhibit the expression of PDLIM2 in cells. These results indicated that KLF10 could transcriptionally regulate the expression of PDLIM2 in RA-FLSs. Overexpression of KLF10 in adipocytes inhibits proliferation and differentiation of adipocytes (31). KLF10 protein can inhibit the proliferation of myoblasts and the activity of fibroblast growth factor receptor 1 promoter (17). However, the role of KLF10 in RA has not been reported. In our experiment, it was found that KLF10 expression was significantly decreased in HFLSs-RA and interfering KLF10 reversed the inhibitory effects of PDLIM2 overexpression on the proliferation, migration and inflammation of HFLSs-RA.

NF-κB protein, which is activated in the inflammatory response, enters the nucleus and activates the transcription of various genes, thus inducing the release of inflammatory factors such as TNF-α, IL-6 and IL-1β (32). Therefore, regulation of NF-κB pathway can manipulate the systemic immune inflammatory response and inhibit the proliferation, promote the apoptosis of FLSs and reduce the differentiation of osteoclasts, thereby reducing inflammation and the erosion of articular cartilage and bone tissue. Thus it can be seen that NF-κB pathway plays an important role in RA. In addition, PDLIM2 can act as a new nuclear regulator of NF-κB (33). In our experiment, it was found that the expression of p-IκBα and p-NF-κB in NF-κB signaling pathway decreased significantly after overexpression of PDLIM2. Further inhibition of KLF10 expression could reverse the inhibitory effect of overexpressed PDLIM2 on the pathway. Therefore, we preliminarily
concluded that KLF10/PDLIM2 modulates the NF-κB pathway and thus plays a role in FLS proliferation and inflammation. In the following experiments, we will further test our conclusion by adding NF-κB pathway inhibitors and pathway inducers.

This article also has some limitations. This conclusion was only obtained in cell experiments, and has not been further verified in animals. We will further prove this in the following experiments. In addition, we found that overexpression of PDLIM2 can induce apoptosis of HFLSs-RA. However, the specific role of apoptosis in this study was not further discussed in this paper due to workload problems. We will also further verify this in the following experiments.

**Conclusion**

In conclusion, our paper confirms that KLF10 up-regulates PDLIM2 by regulating the NF-κB pathway to inhibit proliferation and inflammatory response of FLS in RA. Our experimental results provide a theoretical basis for the mechanism exploration of RA.

**Research highlight**

KLF10 regulates PDLIM2 transcription

KLF10 inhibit proliferation and inflammatory in rheumatoid arthritis

KLF10 up-regulates PDLIM2 via NF-κB pathway

**Consent for publication**

All authors read and approved the final manuscript and agree to publish the article.

**Availability of data and materials**

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

**Disclosure statement**

The authors declare that they have no competing interests.

**Funding**

The author(s) reported there is no funding associated with the work featured in this article.

**References**

[1] Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038. PubMed PMID: 27156434.

[2] Sparks JA. Rheumatoid Arthritis. Ann Intern Med. 2019;170(1):ITC1–ITC16. PubMed PMID: 30596879.

[3] Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–1108. PubMed PMID: 20870100.

[4] Filippucci E, Cipolletta E, Mashadi Mirza R, et al. Ultrasound imaging in rheumatoid arthritis. Radiol Med. 2019;124(11):1087–1100. PubMed PMID: 30852792.

[5] Nygaard G, Firestein GS. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat Rev Rheumatol. 2020;16(6):316–333. PubMed PMID: 32393826; PubMed Central PMCID: PMC7987137.

[6] Bustamante MF, Garcia-Carbonell R, Whisenant KD, et al. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110. PubMed PMID: 28569176; PubMed Central PMCID: PMCPMC5452638.

[7] Tabaries S, McNulty A, Ouellet V, et al. Afadin cooperates with Claudin-2 to promote breast cancer metastasis. Genes Dev. 2019;33(3–4):180–193. PubMed PMID: 30692208; PubMed Central PMCID: PMCPMC6362814.

[8] Cui L, Cheng Z, Hu K, et al. Prognostic value of the PDLIM family in acute myeloid leukemia. Am J Transl Res. 2019;11(9):6124–6131. PubMed PMID: 31632581; PubMed Central PMCID: PMCPMC6789254.

[9] Guo Q, Xu J, Shi Q, et al. PDLIM2 protects articular chondrocytes from lipopolysaccharide-induced apoptosis, degeneration and inflammatory injury through down-regulation of nuclear factor (NF)-κB signaling. Int Immunopharmacol. 2020;88:106883. PubMed PMID: 32805696.

[10] Hao YR, Tang FJ, Zhang X, et al. Suppression of NF-kappaB activation by PDLIM2 restrains hepatic lipogenesis and inflammation in high fat diet induced mice. Biochem Biophys Res Commun. 2018;503(2):564–571. PubMed PMID: 29852170.

[11] Kang M, Lee KH, Lee HS, et al. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells. Prostate. 2016;76(3):273–285. PubMed PMID: 26499308.

[12] Fornes O, Castro-Mondragon JA, Khan A, et al. JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2020;48(D1):D87–D92. PubMed PMID: 31701148; PubMed Central PMCID: PMCPMC7145627.

[13] Lee J, Oh AR, Lee HY, et al. Deletion of KLF10 Leads to Stress-Induced Liver Fibrosis upon High Sucrose...
Feeding. Int J Mol Sci. 2020;22(1):331. PubMed PMID: 33396939; PubMed Central PMCID: PMCPMC7794950.

[14] Yang J, Zhang H, Wang X, et al. Kruppel-like factor 10 protects against acute viral myocarditis by negatively regulating cardiac MCP-1 expression. Cell Mol Immunol. 2020. PubMed PMID: 32895486. 10.1038/s41423-020-00539-x.

[15] Huang LT, Chang HW, Wu MJ, et al. Klf10 deficiency in mice exacerbates pulmonary inflammation by increasing expression of the proinflammatory molecule NPRA. Int J Biochem Cell Biol. 2016;79:231–238. PubMed PMID: 27592451.

[16] Zheng L, Lu H, Li H, et al. KLF10 is upregulated in osteoarthritis and inhibits chondrocyte proliferation and migration by upregulating Acvr1 and suppressing inhbB expression. Acta Histochem. 2020;122(3):151528. PubMed PMID: 32156482.

[17] Parakati R, DiMario JX. Repression of myoblast proliferation and fibroblast growth factor receptor 1 promoter activity by KLF10 protein. J Biol Chem. 2013;288(19):13876–13884. PubMed PMID: 23569208; PubMed Central PMCID: PMCPMC3650423.

[18] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408. PubMed PMID: 11846609.

[19] Chen X, Zhang W, Sun L, et al. Tectorigenin protect HUVECs from H2O2-induced oxidative stress injury by regulating PI3K/Akt pathway. Tissue Cell. 2021;68:101475. PubMed PMID: 33385639.

[20] Zhou J, Jiang YY, Chen H, et al. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway. Cell Prolif. 2020;53(2):e12739. PubMed PMID: 31820522; PubMed Central PMCID: PMCPMC7046305.

[21] Wei F, Wang A, Wang Q, et al. Plasma endothelial cells-derived extracellular vesicles promote wound healing in diabetes through YAP and the PI3K/AKT/mTOR pathway. Aging (Albany NY). 2020;12(12):12002–12018. PubMed PMID: 32570219; PubMed Central PMCID: PMCPMC7343472.

[22] Cai C, Min S, Yan B, et al. Mir-27a promotes the autophagy and apoptosis of IL-1beta treated-articular chondrocytes in osteoarthritis through PI3K/AKT/mTOR signaling. Aging (Albany NY). 2019;11(16):6371–6384. PubMed PMID: 31460867; PubMed Central PMCID: PMCPMC6738432.

[23] Chen X, Xu M, Xu X, et al. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer. Mol Cancer. 2020;19(1):106. PubMed PMID: 32552762; PubMed Central PMCID: PMCPMC7298962.

[24] Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4(1):1. PubMed PMID: 29417950 18002.

[25] Williams B, Dharmapatni A, Crotti T. Intracellular apoptotic pathways: a potential target for reducing joint damage in rheumatoid arthritis. Inflamm Res. 2018;67(3):219–231. PubMed PMID: 29164267.

[26] Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233(1):233–255. PubMed PMID: 20193003; PubMed Central PMCID: PMCPMC2913689.

[27] You S, Koh JH, Leng L, et al. The tumor-like phenotype of rheumatoid synovium: molecular profiling and prospects for precision medicine. Arthritis Rheumatol. 2018;70(5):637–652. PubMed PMID: 29287304; PubMed Central PMCID: PMCPMC5920713.

[28] Shi H, Ji Y, Li W, et al. PDLIM2 acts as a cancer suppressor gene in non-small cell lung cancer via the down regulation of NF-kappaB signaling. Mol Cell Probes. 2020;53:101628. PubMed PMID: 32621848.

[29] Jiang X, Chu Z, Cao Y, et al. PDLIM2 prevents the malignant phenotype of hepatocellular carcinoma cells by negatively regulating beta-catenin. Cancer Gene Ther. 2021;PubMed PMID: 33398035. doi:10.1038/s41417-020-00257-6

[30] Jodo A, Shibazaki A, Onuma A, et al. PDLIM7 synergizes with PDLIM2 and p62/Sqstm1 to inhibit inflammatory signaling by promoting degradation of the p65 subunit of NF-kappaB. Front Immunol. 2020;11:1559. PubMed PMID: 32849529; PubMed Central PMCID: PMCPMC7417631.

[31] Liu Y, Peng WQ, Guo YY, et al. Kruppel-like factor 10 (KLF10) is transactivated by the transcription factor C/EBPbeta and involved in early 3T3-L1 preadipocyte differentiation. J Biol Chem. 2018;293(36):14012–14021. PubMed PMID: 30026232; PubMed Central PMCID: PMCPMC6130933.

[32] Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127–148. PubMed PMID: 33337480; PubMed Central PMCID: PMCPMC7799025.

[33] Mankan AK, Lawless MW, Gray SG, et al. NF-kappaB regulation: the nuclear response. J Cell Mol Med. 2009;13(4):631–643. PubMed PMID: 19438970; PubMed Central PMCID: PMCPMC3822870.